Second Sight Medical Products, Inc. (NASDAQ:EYES) went up by 8.75% from its latest closing price compared to the recent 1-year high of $8.96. The company’s stock price has collected 5.61% of gains in the last five trading sessions.
Is It Worth Investing in Second Sight Medical Products, Inc. (NASDAQ :EYES) Right Now?
Plus, the 36-month beta value for EYES is at 2.10. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Second Sight Medical Products, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $10.00, which is -$0.86 below the current price. EYES currently public float of 13.16M and currently shorts hold a 4.65% ratio of that float. Today, the average trading volume of EYES was 492.50K shares.
EYES’s Market Performance
EYES stocks went up by 5.61% for the week, with a monthly drop of -12.61% and a quarterly performance of -33.61%, while its annual performance rate touched -88.87%. The volatility ratio for the week stands at 8.08% while the volatility levels for the past 30 days are set at 8.55% for Second Sight Medical Products, Inc.. The simple moving average for the period of the last 20 days is 3.17% for EYES stocks with a simple moving average of -68.11% for the last 200 days.
Analysts’ Opinion of EYES
Many brokerage firms have already submitted their reports for EYES stocks, with Dougherty & Company repeating the rating for EYES by listing it as a “Buy.” The predicted price for EYES in the upcoming period, according to Dougherty & Company is $2 based on the research report published on December 13th of the previous year 2019.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see EYES reach a price target of $21. The rating they have provided for EYES stocks is “Buy” according to the report published on July 6th, 2015.
EYES Trading at -1.50% from the 50-Day Moving Average
After a stumble in the market that brought EYES to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.41% of loss for the given period.
Volatility was left at 8.55%, however, over the last 30 days, the volatility rate increased by 8.08%, as shares sank -6.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.90% lower at present.
During the last 5 trading sessions, EYES rose by +19.30%, which changed the moving average for the period of 200-days by -87.90% in comparison to the 20-day moving average, which settled at $0.8295. In addition, Second Sight Medical Products, Inc. saw -86.69% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at EYES starting from McGuire Jonathan Will, who sold 1,793 shares at the price of $5.44 back on Feb 20. After this action, McGuire Jonathan Will now owns 23,826 shares of Second Sight Medical Products, Inc., valued at $9,754 using the latest closing price.
Stock Fundamentals for EYES
Current profitability levels for the company are sitting at:
- -905.50 for the present operating margin
- +36.31 for the gross margin
The net margin for Second Sight Medical Products, Inc. stands at -994.14. The total capital return value is set at -472.14, while invested capital returns managed to touch -528.01. Equity return is now at value -491.60, with -223.00 for asset returns.
Based on Second Sight Medical Products, Inc. (EYES), the company’s capital structure generated 35.77 points at debt to equity in total, while total debt to capital is 26.34.
When we switch over and look at the enterprise to sales, we see a ratio of 23.26, with the company’s debt to enterprise value settled at 0.03. The receivables turnover for the company is 7.05 and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.88.